The Bullish Case: Unlike most cannabis companies, Cronos is actually positioned fairly well with minimal debt on its balance sheet and a positive revenue per share ratio. Much of the financial strength does come from its relationship with Altria (NYSE:MO), which owns a 45% stake in Cronos. This strategic partnership could pay even more dividends down the road if Cronos can utilize Altria’s distribution system throughout the United States. Cronos has also developed a strategy that sets them apart from other farming cannabis companies like Aurora (NYSE:ACB). Instead of being weighed down by an oversupply of cannabis like other farmers, Cronos has focussed on investing in marijuana supplies like vapes and fermentation technology, which could potentially allow Cronos to create pot without the need for marijuana plants at all. Cronos is still bleeding money, but in an industry where mergers and acquisitions are allowing the leaders to become more concentrated, Cronos certainly has the funds to make some moves.